Ligand Pharmaceuticals Incorporated · NASDAQ:LGND
Ligand Pharmaceuticals — 11th Annual BIO CEO & Investor Conference (February 2009)
35 slides from Ligand Pharmaceuticals's conference presentation, Feb 9, 2009
Slide 1: 11th Annual BIO CEO & Investor Conference
Exhibit 99.1 11th Annual BIO CEO & Investor Conference John L. Higgins President and Chief Executive Officer Martin Meglasson Vice President of Discovery Research 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement During the course of this presentation, we may make projections or other forward-looking statements regarding future events or the future financial performance of the company. We wish to caution you that these statements are only predictions and that actual events or results ma
Slide 3: Ligand Company Overview
Ligand Company Overview • Company with strong fundamentals Diverse royalty partnerships with promising potential revenue and profits Robust product pipeline Cost-efficient R&D business with spending discipline • Leverages highly successful drug discovery capabilities Focus on early stage drug discov
Slide 4: Ligand – Recent events
Ligand – Recent events • PROMACTA® approved for chronic ITP • FABLYN® received Complete Response letter in the US, Positive EU advisory panel recommendation • Signed license agreement with GSK for Ligand's TPO program for $158 million in potential payments plus 16% royalty on any future sales • Clos
Slide 5: Why Own Ligand?
Why Own Ligand? Great assets - Two royalty streams, with one being PROMACTA approved 4Q08 - Nine pharma deals, over 20 molecules in development with over a half billion dollars of potential milestones - Powerful and proven drug discovery engine Great track record - Clear communication and transparen
Slide 6: Significant Value in Royalty Partnerships
Significant Value in Royalty Partnerships • Numerous deals with nine pharmaceutical companies • Over 15 programs in various stages of research and development in partnership portfolio • More than 20 different therapeutic indications being pursued including the largest untapped markets Muscle wasting
Slide 7: Strong Partnerships
Strong Partnerships & ofp Schering-Plough GlaxoSmithKline Pfizer, 6 Bristol-Myers Squibb Wyeth (e}, Cephalon y =~ ) King Pharmaceuticals Keene © LIGAND’
Slide 8: Combined Product Pipeline
Combined Product Pipeline Multiple AVINZA®: PROMACTA™ VIVIANT™ /APRELA ™ FABLYN® PROMACTA™ PS433540 SCH5271 23 PS291822 BMS582949 SCH? 27965 LGD-4665 PS386113 PS948115 PS248288 PS873266 PS178990 Erythropoietin (EPO) SGRM PS031291 BACE Inhibitor Indication Chronic Pain ITP Osteoporosis Osteoporosis H
Slide 9: SERM Collaborations
SERM Collaborations • Bazedoxifene (VIVIANT) Monotherapy: Received third FDA approvable letter for osteoporosis in May 2008 & • Expects to file complete response with FDA 1H09: Submitted NDA for osteoporosis treatment in 3Q07 Submitted MAA for osteoporosis prevention & treatment in 3Q07 • Bazedoxife
Slide 10: SERM Collaborations
SERM Collaborations • Lasofoxifene (FABLYN) for osteoporosis treatment • NDA pending approval; FDA issued Complete Response Letter in January 2009 & • FDA Panel had positive vote (9-3) on September 8, 2008 that there is a population of postmenopausal women with osteoporosis in which the benefit of t
Slide 11: Collaboration Highlights
Collaboration Highlights p38 Kinase Inhibitors • Collaboration began in November 1997 • Partnership resulted in lead and back-up p38 kinase inhibitor compounds & • Anti-inflammatory therapeutics Ongoing Clinical Trials: • Phase II in rheumatoid arthritis • Phase II in psoriasis • Phase II in atheros
Slide 12: Collaboration Highlights
Collaboration Highlights Chemokine Receptor CXCR2 Program • Collaboration began in October 1998 • Collaboration produced multiple drug & candidates Clinical Trials: • Phase II in COPD • Phase II in asthma • Phase II in psoriasis completed The Opportunity: • Large, established target markets • Ongoin
Slide 13: Collaboration Highlights
Collaboration Highlights Other Research Program Ongoing Clinical Trials: • Enzyme inhibitor in Phase II for oncology & • Candidate for inflammatory diseases in Phase I • Candidate for respiratory diseases in Phase I Recent Event: • BACE inhibitor for Alzheimer’s in development, resulting in a milest
Slide 14: Collaboration Highlights
Collaboration Highlights Organon Collaboration • Collaboration began in February 2007 with a five-year term & • $4 million per year in research funding • Generation of lead compounds at targets in multiple therapeutic areas selected by Schering-Plough • Success-based milestone payments and up to dou
Slide 15: Collaboration Highlights
Collaboration Highlights Broad Discovery Program • Collaboration began March 2006 • Identify and advance molecules in chosen & therapeutic programs to development stage Milestone and Royalty: • 6 compounds identified to date • Success-based milestone payments and up to double-digit royalties upon co
Slide 16: Collaboration Highlights
Collaboration Highlights Jak-3 Kinase • Collaboration began in December 2006 & $3 million per year in research funding • Alliance based on development of JAK3 kinase inhibitors for systemic administration for immunological and inflammatory diseases • Success-based milestone payments and up to double
Slide 17: Collaboration Highlights
Collaboration Highlights c-Jun N-terminal Kinase Program • Collaboration began in January 2003 • Research activities of the agreement completed Ongoing Clinical Trial: • Phase I in inflammation Broad Discovery • Collaboration began in May 2006 • Drug discovery, development and commercial alliance 17
Slide 18: For medication access and resources for you
For medication access and resources for you ‘and your patients, go to www.PROMACTACARES.com of call 1-877-9-PROMACTA (1-877-977-6622) to enroll, Please see accompanying full Prescribing Information, including BOXED WARNING. © LIGAND
Slide 19: Collaboration Highlights
Collaboration Highlights • PROMACTA approved for treatment of & thrombocytopenia in patients with chronic immune ITP in November 2008. • LGD-4665 and other Ligand TPO molecules licensed to GSK in December 2008 • Hepatitis C: Two Phase III trials were initiated in 4Q07, Phase III in CLD, Phase II Hep
Slide 20: Thrombocytopenia - Causes of Disease
Thrombocytopenia - Causes of Disease Thrombocytopenia is a condition in which there is an abnormally low level of platelets in the blood. • Decreased production of platelets Myelodysplastic syndrome Hepatitis C Cancer in the bone marrow (leukemia) Aplastic anemia • Increased destruction of platelets
Slide 21: Platelets Are #1 at ASH in 2008
21 éting a? the Amenean Socizty of Phaate lug, Issue 3, Section A Monday. December 4, 2008 Platelets Are #1 at ASH In 2008! By Jes cas ML aso af platelet, D.. Fesacanw Zep itm Uwe Un verte) of Udine te Ty, Devsemid ahawace BL at Ieee Pheey Session sth Ins shay at ets nna in skapadie theonkosraperle
Slide 22: Medical Significance of Thrombocytopenia (US)
Medical Significance of Thrombocytopenia (US) (Estimated markets) Potential Treatable Patients ITP ~60,000 Hepatitis C ~120,000 Chronic Liver Disease ~400,000 Myelodysplastic syndrome ~20,000 Leukemia / lymphoma ~50,000 Chemotherapy induced thrombocytopenia ~140,000 Intensive care unit – acquired ~5
Slide 23: R&D Program Highlights
R&D Program Highlights Internal Programs Dr. Martin Meglasson Vice President of Discovery Research
Slide 24: Program Highlights
Program Highlights • Dual Acting Receptor Antagonist (DARA) • Chemokine Receptor (CXCR2 ) • p38 MAP Kinase • Chemokine Receptor (CCR1) • Selective Androgen Receptor Modulator (SARM) 24
Slide 25: PS-433540 Dual Acting Receptor Antagonist
PS-433540 Dual Acting Receptor Antagonist First-in-class Dual Acting Angiotensin and Endothelin Receptor Antagonist (DARA) • A potent, selective blocker of the angiotensin type 1 receptor (AT 1) and the endothelin A receptor (ETA) • Combines the properties of two marketed product classes – AT 1 and
Slide 26: PS-433540 Dual Acting Receptor Antagonist Program
PS-433540 Dual Acting Receptor Antagonist Program • A comprehensive dataset has been compiled Clinical studies – 7 Phase I studies in normal volunteers have been completed – 2 Positive Phase II studies in hypertensive patients have shown statistically significant reductions in blood pressure – Clini
Slide 27: Preliminary Results of Phase IIb Hypertension Study
Preliminary Results of Phase IIb Hypertension Study Most Hypertensive Patients Achieve Blood Pressure Goal (< 140/90) with Once-Daily PS-433540 for 12-weeks PS433540 Placebo 200 mg 400 mg 800 mg Irbesartan N=59 N=58 N=58 N=28 N=58 75.0 *# * 50.0 61.5 51.9 % * * 36.2 25.0 31.5 9.3 0.0 * P<0.01 vs pla
Slide 28: Chemokine Receptor CXCR2 Antagonists for Inflammatory Lung Disease
Chemokine Receptor CXCR2 Antagonists for Inflammatory Lung Disease • CXCR2 is the receptor for the inflammatory cytokine IL-8 • Neutrophilic inflammation and increased IL-8 production are present in chronic lung diseases, e.g., COPD and allergic asthma • CXCR2 receptor antagonists blocks neutrophil
Slide 29: Chemokine Receptor CXCR2 Blockers for Lung Disease
Chemokine Receptor CXCR2 Blockers for Lung Disease • SCH-527123 / PS-291822 Program Status Jointly discovered by Schering-Plough and Ligand Clinical trials have been conducted in multiple inflammatory diseases 2 Phase II clinical trials in asthma are currently underway Phase II study in smokers with
Slide 30: P38 MAP Kinase Inhibitors for Inflammatory Diseases
P38 MAP Kinase Inhibitors for Inflammatory Diseases • P38 MAP kinase is highly expressed in leukocytes • P38 is activated in monocytes by bacterial products causing the secretion of TNF and IL-1 • Proof-of-concept for P38 inhibitors has been established in rheumatoid arthritis and psoriasis by explo
Slide 31: BMS-582949 / PS-540466 P38 Inhibitor
BMS-582949 / PS-540466 P38 Inhibitor • Jointly discovered by BMS and Ligand • Multiple Phase II studies ongoing in inflammatory diseases Plaque psoriasis Rheumatoid arthritis Atherosclerosis • Phase I clinical results presented at 2008 ACR Annual Meeting showed BMS-582949 was well tolerated by norma
Slide 32: Chemokine Receptor CCR1 Antagonist Program Status
Chemokine Receptor CCR1 Antagonist Program Status • CCR1 is the receptor on neutrophils and monocytes for the cytokines MIP-1 and RANTES • Multiple potential indications for CCR1 antagonists – rheumatoid arthritis, psoriasis, asthma • Ligand’s CCR1 antagonist PS-031291 Superior drug distribution pro
Slide 33: Selective Androgen Receptor Modulator Program
Selective Androgen Receptor Modulator Program • Androgens (e.g. testosterone) are steroids that play key roles in bone, skeletal muscle and libido • Current androgenic drugs have disadvantages that significantly limit their use Non-selective stimulation of all androgen receptors Inconvenient formula
Slide 34: Ligand's Expanded SARM Portfolio
Ligand’s Expanded SARM Portfolio • PS-178990 added to Ligand’s SARM portfolio in Pharmacopeia transaction • LGD-4033, LGD-3303, and PS-178990 are chemically differentiated Broadens our I.P. estate with 3 distinct patent families Reduces chemical risks to successful development • PS-178990 Highly pot
Slide 35: Why Own Ligand?
Why Own Ligand? Great assets - Two royalty streams, with one being PROMACTA approved Q4 2008 - Nine pharma deals, over 20 molecules in development with over a half billion dollars of potential milestones - Powerful and proven drug discovery engine Great track record - Clear communication and transpa
Ligand Pharmaceuticals — 11th Annual BIO CEO & Investor Conference (February 2009) on 6ix